OTCMKTS:GNWSF

StageZero Life Sciences Stock Forecast, Price & News

$0.06

0.00 (0.00%)

(As of 06/30/2022 12:00 AM ET)

Add

Compare

Today's Range: $0.06
▼
$0.06
50-Day Range: $0.06
▼
$0.09
52-Week Range: $0.00
▼
$1.27

Volume: 1,000 shs
Average Volume: 26,719 shs
Market Capitalization: $4.00 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

30 days | 90 days | 365 days | Advanced Chart

Receive GNWSF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for StageZero Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

GNWSF Stock Forecast (MarketRank)

Overall MarketRank^™

0.91 out of 5 stars

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for StageZero Life Sciences.

4.5 Community Rank

Outperform Votes
StageZero Life Sciences has received 71 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
StageZero Life Sciences has received 32 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
StageZero Life Sciences has received 68.93% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about StageZero Life Sciences and other stocks. Vote “Outperform” if you believe GNWSF will outperform the S&P 500 over the long term. Vote “Underperform” if you believe GNWSF will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
StageZero Life Sciences does not currently pay a dividend.
Dividend Growth
StageZero Life Sciences does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, StageZero Life Sciences insiders have not sold or bought any company stock.
Percentage Held by Institutions
Only 0.02% of the stock of StageZero Life Sciences is held by institutions.

0.0 Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of StageZero Life Sciences is -0.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of StageZero Life Sciences is -0.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

About StageZero Life Sciences (OTCMKTS:GNWSF)

StageZero Life Sciences Ltd. develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications. Its proprietary platform technology is Sentinel Principle, which identifies novel biomarkers from whole blood. The company's lead product is ColonSentry, a blood test to determine an individual's current risk for having colorectal cancer. It also offers Aristotle, a multi-cancer panel test for simultaneously screening for 10 cancers from a single sample of blood with high sensitivity and specificity for each cancer; and COVID PCR testing and blood test analysis. StageZero Life Sciences Ltd. is headquartered in Richmond Hill, Canada.

June 28, 2022 | finanznachrichten.de

StageZero Life Sciences Ltd: StageZero Life Sciences Announces Results on Resolutions at Annual and Special Meeting

May 26, 2022 | finanznachrichten.de

StageZero Life Sciences Ltd: StageZero Life Sciences Announces Resignation of CFO

May 26, 2022 | apnews.com

StageZero Life Sciences Announces Resignation of CFO

May 25, 2022 | finanznachrichten.de

StageZero Life Sciences Ltd: StageZero Life Sciences Partners with DiagnoseAtHome to Offer Aristotle Multi-Cancer Blood Test in Canada and USA

May 17, 2022 | seekingalpha.com

StageZero Life Sciences Ltd. (SZLSF) CEO James Howard-Tripp on Q1 2022 Results - Earnings Call Transcript

May 15, 2022 | finanznachrichten.de

StageZero Life Sciences Ltd: StageZero Life Sciences Launches COC Plus Worldwide

May 13, 2022 | baystreet.ca

StageZero Life Sciences

May 13, 2022 | finanznachrichten.de

StageZero Life Sciences Ltd: StageZero to Issue Q1 2022 Financial Results and Hold Conference Call on Tuesday May 17

March 29, 2022 | finanznachrichten.de

StageZero Life Sciences Ltd: StageZero to Issue Q4 2022 Financial Results and Hold Conference Call on Friday April 1

March 3, 2022 | finanznachrichten.de

StageZero Life Sciences Ltd.: StageZero Life Sciences Announces Closing of CAD$1.87 Million Private Placement with Institutional Investor

February 28, 2022 | finanznachrichten.de

StageZero Life Sciences Ltd: StageZero Life Sciences Announces CAD$1.87 Million Private Placement with Institutional Investor

December 14, 2021 | finanznachrichten.de

StageZero Life Sciences Ltd: StageZero Life Sciences Announces Formation of Scientific Advisory Board

December 13, 2021 | finanznachrichten.de

StageZero Life Sciences Ltd: StageZero Life Sciences Named a COVID-19 Travel Testing Partner for Aruba

See More Headlines

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Industry: Diagnostic substances
Sub-Industry: N/A
Sector: Medical
Current Symbol: OTCMKTS:GNWSF
CUSIP: N/A
CIK: 1454263
Web: www.stagezerolifesciences.com
Phone: 905-209-2030
Fax: N/A
Employees: 51
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-6.86 million
Net Margins: -200.26%
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: -165.13%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.15
Quick Ratio: 1.08

Sales & Book Value

Annual Sales: $4.15 million
Price / Sales: 0.96
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.02) per share
Price / Book: -3.17

Miscellaneous

Outstanding Shares: 62,995,000
Free Float: N/A
Market Cap: $4.00 million
Optionable: Not Optionable
Beta: 0.28

StageZero Life Sciences Frequently Asked Questions

How has StageZero Life Sciences' stock price performed in 2022?: StageZero Life Sciences' stock was trading at $0.2303 at the beginning of 2022. Since then, GNWSF stock has decreased by 72.4% and is now trading at $0.063450.
View the best growth stocks for 2022 here.
Who are StageZero Life Sciences' key executives?: StageZero Life Sciences' management team includes the following people:
Mr. James R. Howard-Tripp, Exec. Chairman & CEO
Mr. Carl Solomon, Interim Chief Financial Officer
Prof. Choong-Chin Liew, Co-Founder
Mr. Warren Whitehead C.M.A., Chief Accountant (Age 69)
Mr. David Suria, Sr. Scientist
Who are some of StageZero Life Sciences' key competitors?: Some companies that are related to StageZero Life Sciences include StageZero Life Sciences (SZLSF), StageZero Life Sciences (GNWSD), Global WholeHealth Partners (GWHP), FluoroPharma Medical (FPMI), BG Medicine (BGMD), Hemagen Diagnostics (HMGN) and Response Genetics (RGDXQ).
View all of GNWSF's competitors.
What is StageZero Life Sciences' stock symbol?: StageZero Life Sciences trades on the OTCMKTS under the ticker symbol "GNWSF."

How do I buy shares of StageZero Life Sciences?: Shares of GNWSF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is StageZero Life Sciences' stock price today?: One share of GNWSF stock can currently be purchased for approximately $0.06.
How much money does StageZero Life Sciences make?: StageZero Life Sciences (OTCMKTS:GNWSF) has a market capitalization of $4.00 million and generates $4.15 million in revenue each year.
How many employees does StageZero Life Sciences have?: StageZero Life Sciences employs 51 workers across the globe.
How can I contact StageZero Life Sciences?: StageZero Life Sciences' mailing address is 70 East Beaver Creek Road Unit 30, Richmond Hill A6, L4B 3B2. The official website for StageZero Life Sciences is www.stagezerolifesciences.com. The company can be reached via phone at 905-209-2030 or via email at [email protected].

This page (OTCMKTS:GNWSF) was last updated on 7/1/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

MarketBeat Resources